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Mixed Alkyl Aryl Phosphonate Esters as Quenched 
Fluorescent Activity-Based Probes for Serine 
Proteases 
Sevnur Serim,a Philipp Baera and Steven H. L. Verhelst* a,b 
Activity-based probes (ABPs) are powerful tools for the analysis of active enzyme species in 
whole proteomes, cells or animals. Quenched fluorescent ABPs (qABPs) can be applied for 
real time imaging, allowing the visualization of dynamic enzyme activation by fluorescent 
microscopy. Unfortunately, qABPs are only available for a few enzymes. We here describe the 




During the last decade, chemical proteomics has increasingly 
been used for the functional characterization of proteins within 
the context of a whole proteome. In contrast to classical 
proteomics approaches, the technique of activity-based protein 
profiling (ABPP) can distinguish between active and inactive 
enzyme species by using small molecule activity-based probes 
(ABPs).1-3 ABPs rely on a reactive group or ‘warhead’ that 
covalently binds to the active site of a specific subset of 
enzymes, often in a mechanism-based reaction with an active 
site nucleophile. A reporter tag on the ABP, such as a biotin or 
a fluorophore, enables subsequent detection of the covalent 
complex (Fig. 1A).4 ABPs have been applied for various 
purposes including the profiling of enzyme activities in disease 
models and the screening of enzyme inhibitors in complex 
proteomes.5-7 
 ABPs have proven especially useful for the study of 
proteases,8 since these enzymes are generally synthesized as 
inactive zymogens and are tightly regulated by post-
translational processes. Fluorophore-labeled ABPs do not only 
allow detection of active proteases after gel electrophoresis, but 
also enable the direct visualization in cells, tissue sections or 
live animals by microscopy techniques. However, the intrinsic 
fluorescence of these ABPs requires extensive washing of cells 
in culture or long clearance times in vivo in order to remove 
unreacted probe and obtain sufficient contrast, preventing real-
time imaging applications. Quenched fluorescent ABPs 
(qABPs) have been developed to overcome this problem. They 
rely on a reactive warhead that carries a leaving group to which 
a fluorescence quencher is attached. This results in an overall 
dark probe, which only lights up after reaction with the target 
enzyme (Fig. 1B). The synthesis of qABPs is challenging and 
thus far, qABPs have only been reported for the clan CA and 
clan CD cysteine proteases and for selected phosphatases.9-13 In 
our continuous efforts to develop novel probes for serine 
proteases, we here describe the design and synthesis of the first 
qABPs for serine proteases based on mixed alkyl, aryl 
phosphonates. 
 
Fig. 1 Activity-based probes and their quenched fluorescent versions. 
A) The general approach of activity-based protein profiling. The 
detection tag, here depicted as a light bulb, can range from a 
fluorophore, biotin or radiotracer to a bioorthogonal detection handle 
such as an azide or alkyne. B) Fluorescently quenched activity-based 
probes rely on reactive warhead with a leaving group that contains a 
fluorescence quencher. C) A diphenyl phosphonate (R and Aryl = Ph) 
or alkyl, aryl phosphonate (R = alkyl) and the covalent attachment to 














1 R1 = i-Pr, R2 = Cbz
2 R1 = pNO2-Ph, R2 = Cbz
3 R1 = pNO2-Ph, R2 = H









5 R1 = i-Pr, R2 = Cbz










8 R1 = i-Pr, R2 = Cbz
9 R1 = i-Pr, R2 = H
10 R1 = i-Pr, R2 = hexynoyl











12 R = Boc










Scheme 1. Synthesis of the mixed ethyl aryl phosphonate building blocks 10 and 13. a) Cbz-NH2, diethyl phosphite, AcCl, 0 °C, 
1h, 88-95%. b) 33% HBr/AcOH, 1h. c) hexynoic acid, HATU, DIEA, DMF, overnight, 74% over 2 steps for compound 4, 26% 
over 2 steps for compound 10. d) LiBr, 2-butanone, 70 °C, overnight, 65-83%. e) 7, DIC, DMAP, toluene, 70 °C, overnight, 96% 
(for compound 8)  f) H2, Pd-C, overnight. g) SnCl2, EtOH, 70 °C, 1h, then 1,3-di-Boc-2-(trifluoromethyldulfonyl)guanidine, TEA, 
CH2Cl2, overnight, 17% (for compound 12, 3 steps from 6).  h) TFA/CH2Cl2 1/1, 1h, 37%. i) Boc2O, Na2CO3, dioxane/H2O, 1h, 
90%. 
 
Scheme 2. Synthesis of the qABPs 14 and 15. a) TAMRA-NH-(CH2)3-N3, Cu(I), THF, overnight. b) TFA/CH2Cl2 1/1, 1h (for 
compound 10 only). c) QSy7-OSu, DIEA, dmso, 3h, 3-16% over 3 steps. 
 
Results and Discussion 
In the past, ABPs for serine protease have utilized several types 
of electrophilic moieties as warheads, including 
fluorophosphonates,14, 15 sulfonyl fluorides16 and 
isocoumarins.17-19 However, these do not contain leaving 
groups that can be used for the incorporation of a fluorescence 
quencher moiety. -Amino diphenyl phosphonates (DPPs), 
however, contain a phenoxy leaving group, which is expulsed 
upon reaction with the active site serine of a serine protease 
(Fig. 1C). Furthermore, the selectivity of DPPs can be adjusted 
by varying the P1 element as well as by elongation with a 
longer peptide. Therefore, DPPs have been used as potent and 
selective serine protease inhibitors and ABPs.20, 21 In the design 
for qABPs, it is of crucial importance that the reactive group 
contains one single leaving group, making diaryl phosphonates 
unsuitable. To overcome this problem, we synthesized qABPs 
as mixed alkyl aryl phosphonates, which we made from dialkyl 
phosphonates by selective removal of one alkyl group, 
subsequent introduction of the aryl leaving group, and finally 
introduction of the fluorophore and the quencher. 
 The starting point of the synthesis consisted of an aldehyde, 
which will form the P1 element that is recognized by the S1 
pocket of the target serine protease. The aldehyde was reacted 
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with diethyl phosphite and benzyl carbamate in a Mannich-type 
condensation,22 forming the phosphonate scaffold (Scheme 1). 
In order to target elastase-like proteases, isobutyraldehyde was 
used to form the valine-like phosphonate 1. For trypsin-like 
proteases, p-nitrobenzaldehyde was chosen as a starting 
material, giving phosphonate 2 with a p-nitrophenyl group. At a 
later stage, this group can be transformed into a p-guanidino-
phenyl substituent, a mimic of the arginine side chain.23 The 
Cbz protecting group of 2 was removed with HBr/AcOH and 
the free amine was coupled to a hexynoic acid. The terminal 
alkyne handle will allow the introduction of a fluorophore by 
mild click chemistry conditions, which are compatible with the 
base-labile aryl phosphonate functional group. For the selective 
hydrolysis of one ethyl group, we initially used saponification 
with NaOH. However, this reaction resulted in a mixture of 
products. Gratifyingly, a non-hydrolytic mono-dealkylation by 
SN2 substitution using LiBr in refluxing 2-butanone24 yielded 
the desired product. A Boc-protected tyramine (7) was 
introduced by carbodiimide-mediated esterification. For the 
valine-like molecule, the transformation to a mixed alkyl aryl 
phosphonate ester was more efficient before introduction of the 
hexynoic acid group (Scheme 1). We reduced the nitro-group of 
compound 11 with SnCl2 and reacted the free amine with di-
Boc-2-(trifluoromethylsulfonyl)guanidine, followed by Boc-
deprotection yielding building block 13. 
 With the two alkyl aryl phosphonates 10 and 13 in hand, the 
stage was set to introduce the fluorophore and quencher groups. 
First, a tetramethylrhodamine(TMR)-functionalized azido-
propylamine was coupled by Cu(I)-catalyzed cycloaddition. 
Subsequently, a succinimide derivative of QSy7, a powerful 
fluorescent quencher, was coupled to the amino-function of the 
tyramine leaving group, yielding qABPs 14 and 15 (Scheme 2). 
 After the successful synthesis of the two serine protease 
qABPs, we aimed for a basic evaluation of their labeling and 
quenching properties. Activity-based labeling by qABPs 14 and 
15 was tested on purified serine proteases of different 
specificities: trypsin and urokinase plasminogen activator, 
which have preference for basic P1 side chains, chymotrypsin 
and cathepsin G, which prefer large hydrophobic P1 side 
chains, and pancreatic elastase and neutrophil elastase which 
show selectivity for small hydrophobic P1 side chains. As 
expected, the reactivity matched the natural substrate specificity 
of the target proteases (Fig. 2A): probe 15 containing the P1 
arginine mimic strongly labeled the trypsin-like proteases, 
whereas the P1 valine probe 14 showed intense labeling of 
neutrophil elastase, which prefers a P1 valine residue. Probe 14 
displayed weaker labeling of chymotrypsin and pancreatic 
elastase, which have preference for large hydrophobic and 
alanine residues, respectively. To show sensitivity of the alkyl, 
aryl phosphonate qABPs, we labeled a decreasing amount of 
trypsin with probe 15 and found that as little as 2 ng of this 
protease target could be detected (Fig. S1†). Additionally, we 
performed labeling of trypsin in the presence of a crude lysate 
of the human cancer cell line HT-29. The detectable amount of 
trypsin was 0.025% of total protein, comparable to other serine 
protease probes19 (Fig. S2†). 
 For imaging applications, it is of fundamental importance 
that there is a clear difference between the probe’s fluorescence 
in the unbound/quenched state and the bound/unquenched state. 
We tested this by incubation of probe 15 in PBS with or 
without bovine trypsin as a target protease. Satisfyingly, the 
signal of the probe was similar to the used buffer, which 
indicates both the strongly quenched TAMRA fluorescence and 
the probe stability at physiological pH. As expected, a rapid 
increase in fluorescence occurred upon reaction with the 




Fig. 2. Evaluation of serine protease qABPs. A) Labeling of serine 
proteases with qABPs 14 and 15 (Try = bovine trypsin, uPA = human 
urokinase plasminogen activator, CatG = human cathepsin G, Ctry = 
bovine chymotrypsin, PPE = porcine pancreatic elastase, NE = human 
neutrophil elastase). Each sample was treated with dmso (-) or an 
inhibitor (+) before incubation with the qABP. The used inhibitors 
included DCI for trypsin and elastase, DFP for uPA, PMSF for 
cathepsin G and DAP22c for chymotrypsin. B) qABP 15 (2 M) was 
incubated in PBS with or without bovine trypsin (0.05 mg/mL) and the 
fluorescence (ex: 544 nm, em: 590 nm) was followed in a 96-well plate 
reader for 1 h.  
Conclusions 
Up to date, qABPs have only been developed for cysteine 
proteases9-13 and for tyrosine phosphatases.13 In this paper, we 
have described the first synthesis of qABPs for serine proteases. 
They are based on a phosphonate reactive electrophile that, in 
contrast to previously reported serine protease phosphonate 
ABPs, are mixed alkyl aryl phosphonates. The biochemical 
evaluation shows that the phosphonate qABPs covalently label 
their serine protease targets with expulsion of the fluorescent 
quencher. The selectivity is steered by the P1 element, and may 
be further influenced by introduction of extended recognition 
elements in the P2-P4 positions25 As elevated serine protease 
activities are present in several pathologies such as 
inflammation and tumorigenesis, we expect that the mixed 
alkyl aryl phosphonate qABPs as synthesized here will be 
useful tools for the future study of these processes. Application 
of these probes in complex proteomes and imaging studies by 
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fluorescent microscopy are currently under investigation and 
will be reported in due course. 
Experimental 
Materials and equipment 
Acetic acid, acetyl chloride, human urokinase plasminogen 
activator and porcine pancreatic elastase were purchased at 
VWR (Ismaning, Germany), benzyl carbamate, Boc anhydride, 
chymotrypsin from bovine pancreas type II, copper(I)bromide, 
diethyl phosphite, diisopropylcarbodiimide (DIC), 4-
(dimethylamino)pyridine (DMAP), N-diisopropyl-N-
ethylamine (DIEA),  HBr (33% in acetic acid), 
isobutyraldehyde. lithium bromide, sodium ascorbate, trypsin 
from bovine pancreas type I, and tyramine were obtained from 
Sigma-Aldrich (Taufkirchen, Germany), QSy-7 succinimidyl 
ester was bought from Invitrogen/Life Technologies 
(Darmstadt, Germany), HATU was purchased at Creosalus 
(Louisville, KY, USA), MgSO4 was obtained from Carl Roth 
(Karlsruhe, Germany), and sodium carbonate decahydrate, 2-
butanone and human neutrophil elastase were received from 
Applichem (Darmstadt, Germany). TBTA was made as 
previously described.26 
 Thin layer chromatography (TLC) was performed on 
ALUGRAM sil G/UV254 TLC plates (Carl Roth, Germany). 
Solvents used for reactions and purification via column 
chromatography were purchased from Applichem, Germany. 
Compounds were separated over silica gel with a grain 
distribution of 0.04-0.063 mm and a pore size of 60 Å (Carl 
Roth, Germany). 
 LC-MS spectra were recorded by an Agilent 1100 Series 
LC system coupled to an Agilent 6210 ESI TOF mass 
spectrometer, with separation on a  Zorbax SB C18 5 µm (0.5 x 
150 mm) column and elution by solvents A (5 % MeCN/H2O + 
0.1 % formic acid) and B (95 % MeCN/H2O + 0.1 % formic 
acid) at a flowrate of 20 µl/min. HPLC purifications were 
carried out on Waters Xbridge BEH130 Prep C18 5 µm (19 x 
150 mm) column. 1H NMR spectra were measured on a Bruker 
400 MHz DRX or a Bruker 500 MHz Avance III. Chemical 
shifts (δ) are given in parts per million (ppm) relative to 
tetramethylsilane as an internal standard. 
Methods 
General procedure for dealkylation with LiBr. The diethyl 
phosphonate (1 eq.) and LiBr (1.2 eq.) were stirred overnight in 
butanone (5 mL/mmol) under refluxed at 70 °C. The formed 
precipitate was collected by filtration, washed with diethyl 
ether and redissolved in 1 M HCl. The water phase was 
extracted four times with EtOAc and the collected organic 
layers were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. main paragraph text 
follows directly on here. 
General procedure for coupling of 5-hexynoic acid. 5-
hexynoic acid (2 eq.) was preactivated with HATU (1.9 eq.) 
and DIEA (4 eq.) in DMF (4 mL) for 20 min at rt. To this 
mixture, the phosphonate with a free -amino group (1 eq.) and 
DIEA (1.6 eq.) in DMF (3 mL) were added and stirred o/n at rt. 
The solvent was removed, and the oily product was redissolved 
in EtOAc. The organic phase was washed twice with 1 M HCl, 
twice with saturated NaHCO3, and brine. The organic layer was 
dried over MgSO4 and concentrated under reduced pressure. 
Diethyl 1-(N-benzyloxycarbonyl-amino)-2-methyl-
propanephosphonate (1). To a mixture of benzyl carbamate 
(1.51 g, 10 mmol), diethyl phosphite (1.28 mL; 10 mmol) and 
isobutyraldehyde (1.14 mL, 12.5 mmol) cooled at -5 °C was 
added dropwise 15 mL acetyl chloride. The reaction was stirred 
for 1h, warmed to room temperature and the mixture was 
concentrated under reduced pressure. EtOAc was added and the 
organic phase was washed with water, saturated NaHCO3 (2x) 
and brine, dried on MgSO4 and evaporated under reduced 
pressure. Silica column chromatography (50-100% EtOAc in 
petroleum ether) gave the title compound as a colorless oil 
(3.03 g, 88% yield). ESI-MS: m/z 344.1925, C16H27NO5P+ 
requires 344.1621. 1H NMR (400 MHz, CDCl3)  7.38-7.30 (m, 
5H), 5.19-5.08 (m, 3H), 4.16-3.82 (m, 5H), 2.27-2.17 (m, 1H), 
1.34-1.22 (m, 6H), 1.03 (d, 3H, J = 6.8 Hz), 1.0 (d, 3H, J = 6.9 
Hz). 
Diethyl 1-(N-benzyloxycarbonyl-amino)-(4-nitro-
phenyl)methanephosphonate (2). To a mixture of benzyl 
carbamate (0.75 g, 5 mmol), diethyl phosphite (0.64 mL; 5 
mmol) and 4-nitrobenzaldehyde (0.75 g, 5 mmol) cooled at 0 
°C was added dropwise 7.5 mL acetyl chloride. The reaction 
was stirred for 1h, warmed to room temperature and the 
mixture was concentrated under reduced pressure. EtOAc was 
added and the organic phase was washed with water, saturated 
NaHCO3 (2x) and brine, dried on MgSO4 and evaporated under 
reduced pressure. Silica column chromatography (50-100% 
EtOAc in petroleum ether) gave the title compound as a white 
solid (2.01 g, 95% yield). ESI-MS: m/z 423.1368 (found), 
C13H24N2O7P+ requires 423.1316. 1H NMR (500 MHz, DMSO-
d6): δ = 8.64 (d, 1H, J = 9.2 Hz,), 8.23 (d, 2H, J = 8.6 Hz), 7.77 
(2H, d, J = 7.0 Hz), 7.41-7.28 (m, 5H), 5.34 (dd, 1H, J = 23.1 
Hz, J = 9.9 Hz), 5.15 – 5.00 (m, 2H), 4.03-3.87 (m, 4H), 1.16 
(t, J = 7.1 Hz, 3H), 1.12 (t, J = 7.0 Hz, 3H). 
Diethyl 1-(N-hex-5-ynoyl-amino)-(4-nitro-
phenyl)methanephosphonate (4). Compound 1 was with 33% 
HBr/AcOH solution until all the starting material was 
consumed as indicated by TLC. Next, the solvent was removed 
under reduced pressure with coevaporation from toluene, giving 
the product as bright orange solid which was used in the next 
step without purification. 5-hexynoic acid was coupled as 
described under the general procedure. Silica column 
chromatography (60-80% EtOAc in petroleum ether) gave the 
product in 74% yield as yellowish crystals. ESI-MS: m/z 
383.1385 (found), C17H24N2O6P+ requires 383.1366. 1H NMR 
(500 MHz, DMSO-d6): δ = 9.09 (dd, 1H, J = 9.6 Hz, J = 3,0 
Hz), 8.24 (d, 2H, J = 8.5 Hz), 7.74 (dd, 2H, J = 8.8 Hz, J = 1.9 
Hz), 5.63 (dd, 1H. J = 22.5 Hz, J = 9.6 Hz), 4.08-3.84 (m, 4H), 
2.78 (t 1H, J = 2.6 Hz), 2.43-2.28 (m, 2H), 2.19-2.13 (m, 2H), 





propanephosphonate (5). Compound 4 (686 mg, 2.0 mmol) 
was dealkylated with LiBr according to the general procedure 
affording the title compound as a white solid (526 mg, 83% 
yield). ESI-MS: m/z 316.1322 (found), C14H23NO5P+ requires 
316.1308. 1H NMR (400 MHz, CDCl3)  8.72 (s, 1H), 7.36-
7.29 (m, 5H), 5.23-5.12 (m, 3H), 4.12-3.97 (m, 3H), 2.24-2.16 
(m, 1H), 1.26 (t, 3H, J = 7.0 Hz), 1.01 (dd, 3H, J = 6.9 Hz, J = 
0.9 Hz), 0.98 (d, 3H, J = 6.9 Hz). 
Ethyl 1-(N-hex-5-ynylamino)-(4-nitro-phenyl)-
methanephosphonate (6). 3 (918 mg, 2.4 mmol) was 
dealkylated with LiBr according to the general procedure 
affording the title compound as a white powder in 65% yield. 
ESI-MS: [M+H]+ m/z 355.1071 (found), C15H20N2O6P+ requires 
355.1053. 1H NMR (400 MHz, CDCl3)  8.20 (d, 2H, J = 8.6 
Hz), 7.60-7.55 (m, 2H), 7.19-7.14 (m, 1H), 5.59 (dd, 1H, J = 
22.3 Hz, J = 8.8 Hz), 4.04-3.96 (m, 2H), 2.46 (t, 2H, J = 7.2 
Hz), 2.28-2.18 (m, 2H), 1.99 (t, 1H, J = 2.6 Hz), 1.84 (t, 2H, J 
= 7.1 Hz), 1.24 (t, 3H, J = 7.1 Hz). 
N-tert-butyloxycarbonyl-tyramine (7). To tyramine (274 mg; 
2.0 mmol), dissolved in 10 mL dioxane/water (1/1; v/v) was 
added sodium carbonate decahydrate (572 mg; 2 mmol). The 
mixture was cooled in an icebath and Boc anhydride (480 mg; 
1.1 eq) was added. After 1h, the reaction was allowed to warm 
up to room temperature, after which EtOAc was added. The 
mixture was subsequently washed with 1M KHSO4 (2x), water, 
saturated NaHCO3 and brine. The organic phase was dried on 
MgSO4, filtered and concentrated under reduced pressure. 
Silica column chromatography (20-50% EtOAc in petroleum 
ether) yielded the title comound (425 mg; 1.80 mmol; 90%) as 
a slightly yellowish oil which solidified upon standing. ESI-
MS: m/z 238.1447 [M+H]+, 475.2838 [2M+H]+ (found), 
C13H20NO3+ requires 238.1438; C26H39N2O6+ requires 
475.2803. 1H NMR (400 MHz, CDCl3)  7.01 (d, 2H, J = 8.3 
Hz), 6.79 (d, 2H, J = 8.5 Hz), 6.26 (bs, 1H), 4.62 (bs, 1H), 
3.37-3.28 (m, 2H), 2.70 (t, 2H, J = 7.0 Hz), 1.44 (s, 9H). 
4-(N-Boc-2-aminoethyl)-phenyl, ethyl 1-(N-
benzyloxycarbonyl-amino)-2-methyl-propane-phosphonate 
(8). Compound 5 (200 mg, 0.63  mmol) and 7 (165 mg; 0.70 
mmol), coevaporated with toluene, were dissolved in toluene 
(3.5 mL) and stirred at 70 °C. Subsequently, DIC (450 L) and 
DMAP (8 mg) were added, and the solution was stirred 
overnight. The solvent was evaporated under reduced pressure, 
the residue dissolved in EtOAc and subsequently washed with 1 
M KHSO4, water, saturated NaHCO3 and brine. Silica column 
chromatography (20-70% EtOAc in petroleum ether) gave the 
title compound as a white solid (323 mg; 0.60 mmol, 96%). 
ESI-MS: m/z 535.2596 (found), C27H40N2O7P+ requires 
535.2568.  1H NMR (400 MHz, CDCl3)  7.40-7.30 (m, 5H), 
7.14-7.05 (m, 4H), 5.17-5.06 (m, 3H), 4.54 (bs, 1H), 4.25-4.05 
(m, 3H), 3.33 (t, 2H, J = 6.6 Hz), 2.78-2.71 (m, 2H), 2.35-2.26 
(m, 1H), 1.44 (s, 9H), 1.32-1.21 (m, 3H), 1.15-1.03 (m, 6H). 
4-(N-Boc-2-aminoethyl)-phenyl, ethyl 1-(N-hex-5-
ynylamino)-2-methyl-propane-phosphonate (10). Compound 
8 (650 mg, 1.22 mmol) was dissolved in EtOH (4 mL). Pd/C 
(65 mg) and AcOH (143 L; 2.5 eq.) were added and the 
mixture was stirred under 1 atm. hydrogen pressure until all 
starting material had disappeared. The catalyst was filtered off 
and the solvent was evaporated, giving compound 9, which was 
used directly in the next step.  ESI-MS: m/z 401.2218 (found), 
C19H34N2O5P+ requires 401.2200. 5-hexynoic acid was coupled 
as described under the general procedure. The crude product 
was purified by silica column chromatography (50-100% 
EtOAc in petroleum ether), giving the title compound as a 
slightly yellowish oil, which partly solidified upon standing 
(26% over 2 steps). ESI-MS: m/z 495.2809 (found), 
C25H40N2O6P+ requires 495.2618. 1H NMR (400 MHz, CDCl3) 
 7.16 (d, 2H, J = 9.3 Hz), 7.11 (d, 2H, J = 9.3 Hz), 5.94 (dd, 
1H, J = 19.0 Hz, J = 8.1 Hz), 4.66-4.51 (m, 2H), 4.28-4.16 (m, 
2H), 3.37-3.38 (m, 2H), 2.79-2.72 (m, 2H), 2.47-2.22 (m, 5H), 
2.07-1.98 (m, 1H), 1.93-1.77 (m, 2H), 1.44 (s, 9H), 1.34-1.26 
(m, 3H), 1.08-1.01 (m, 6H). 
4-(N-Boc-2-aminoethyl)-phenyl, ethyl 1-(N-hex-5-
ynylamino)-(4-N, N-di-Boc-guanidino-phenyl)-
methanephosphonate (12). Compound 6  (1.0 eq.) and 7 (1.1 
eq.) were dissolved in DMF, and DIC (8 eq.) and DMAP (0.1 
eq.) were added. The reaction was set under N2 and heated 
overnight at 70 °C. The solvent was removed and the oily 
product was redissolved in EtOAc. The organic layer was then 
washed 1x with saturated NaHCO3, 1x with 1 M HCl and brine, 
subsequently dried over MgSO4. The solvent was removed 
under reduced pressure, giving compound 11 as a white 
powder, which was used without further purification. ESI-MS: 
m/z 574.2351 (found), C28H37N3O8P+ requires 574.2313. 
Compound 11 (302 mg, 0.57 mmol) and SnCl2 (536 mg, 5 eq.) 
were mixed in EtOH (2 mL) and refluxed at 70 °C for 1 h. The 
solvent was removed and the oily product was redissolved in 
saturated NaHCO3. The water phase was then extracted 3x with 
EtOAc. The combined organic phases were washed with brine, 
dried over MgSO4 and concentrated under reduced pressure. 
The product was directly used for the next reaction without 
further purification. ESI-MS: m/z 544.2681 (found), 
C28H39N3O6P+ requires 544.2571. The crude product from the 
previous reaction (255 mg, 0.47 mmol) was dissolved in DCM 
and 1,3-di-Boc-2-(trifluoromethylsulfonyl)guanidine (1.6 eq.) 
and TEA (2 eq.) were added. The mixture was refluxed 
overnight. The reaction was diluted with DCM and the organic 
phase was washed with twice with 1M KHSO4, once with 
saturated NaHCO3 and brine and subsequently dried over 
MgSO4. The solvent was removed under reduced pressure and 
the crude product was purified by silica column 
chromatography (isocratic elution with EtOAc/petroleum ether 
1/1). The target compound was isolated as white crystals in 
17% yield over 3 steps. ESI-MS: m/z 786.4120 (found), 
C39H57N5O10P+ requires 786.3838. 1H NMR (500 MHz, DMSO-
d6): δ 11.4 (s, 1H), 10.02 (s, 1H), 9.03 (dd, 1H J = 9.8 Hz, J = 
1.7 Hz,), 7.58-7.52 (m, 2H), 7.48 (d, 2H,  J = 7.1 Hz), 7.17 (d, 
2H, J = 8.5 Hz), 7.02 (d, 2H, J = 8.2 Hz), 6.85 (t, 1H, J = 5.4 
Hz), 5.65 (dd, 1H, J = 21.5 Hz, J = 9.8 Hz), 4.02 (q, 2H, J = 7.2 
Hz), 3.14-3.08 (m, 2H), 2.77 (t, J = 2.6 Hz, 1H), 2.66 (t, 2H, J 
= 7.5 Hz), 2.32-2.26 (m, 2H), 2.16-211 (m, 2H), 1.68 – 1.61 
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(quint, 2H, J = 7.3 Hz), 1.51 (s, 9H), 1.41 (s, 9H), 1.37 (s, 9H), 





(1.1 eq.) and compound  10 (2.0 mol, 1.0 eq.) were mixed 
with CuBr (1 mM), TBTA (2 mM) and sodium ascorbate (10 
mM) in t-BuOH/water 1/1 (50 L). The reaction heated 
overnight at 40 °C under nitrogen, when ESI-MS showed the 
formation of the triazole adduct. ESI-MS: m/z 504.2381 
(found), C53H69N8O10P2+ requires 504.2432. The solvent was 
removed under reduced pressure and the crude compound was 
treated with TFA/DCM (1/1) + 2.5% water (50 L) for 1h. The 
solvent was removed in vacuo and the product was detected by 
ESI-MS: m/z 454.2139 (found), C48H61N8O8P2+ requires 
454.2169. The resulting free amine was coupled to QSy7 
succinimidyl ester (1.1 eq.) in dmso (50 L) with DIEA (1.8 
eq.). After 3h, the reaction mixture was purified by RP-HPLC. 
Product containing fractions were pooled and lyophilized, 
giving probe 14 as a purple powder (16% yield over three 
steps). ESI-MS: m/z 1546.6544 (found), C87H93N11O12PS+ 
requires 1546.6458. 
4-(N- QSy7-2-aminoethyl)-phenyl, ethyl 1-(3-(3-(N-
tetramethylrhodaminylamino)propyltriazolyl)butanoylamin
o)-(4-guanidino-phenyl)-methanephosphonate (15). 
Compound 12 was Boc-deprotected in TFA/DCM (1/1) for 30 
min. The solvent was removed and the oily product was 
purified by HPLC, giving a white power in 37% yield. ESI-MS: 
m/z 486.2244 (found), C24H33N5O4P+ requires 486.2265. The 
product was coupled by click chemistry to TAMRA-propyl-N3 
as described above, purified by HPLC and isolated as a pink 
powder after lyophilization (16%). The QSy-7 succinimidyl 
ester was coupled as described above and the final product 15 
was isolated after HPLC purification in 18% yield as a purple 
powder. ESI-MS: m/z 1638.6591 (found), C91H94N14O12PS+ 
requires 1637.6628. 
Labeling of proteases. Each protease (375 ng) in PBS was 
labeled in a final volume of 50 µL. It was first treated for 30 
min with 1% dmso or an inhibitor (1 mM DCI for trypsin and 
elastase), 100 M DFP for uPA, 1 mM PMSF for cathepsin G 
and 100 M DAP22c for chymotrypsin).  Subsequently, each 
sample was incubated for 30 min with probe 14 (5 M) or 15 (2 
M), which were diluted from a 100x stock in dmso. The 
proteins were resolved on a 15% SDS-PAGE gel (30% of the 
sample volume was loaded) and scanned with a typhoon 
TRIO+ fluorescent scanner. 
Unquenching experiment. The experiment was conducted in a 
black 96-well plate with each sample volume equaling 100 L. 
As a blank control 98 L PBS and 2 L dmso were used. 
Compound 15 (2 L from a 100 M dmso stock) and 98 L 
PBS constituted the no protease control, whereas compound 15 
(2 L from a 100 M dmso stock), 93 L PBS and 5 L bovine 
trypsin (1 mg/mL in PBS) were mixed to observe the 
unquenching. The reactions were followed for 120 min in a 
fluorimeter (FLUOstar OPTIMA, BMG labtech) with an 
excitation filter of 544 nm and emission filter of 590 nm). 
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